Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

PubMed (MeSH Keyword) for PubChem Compound (Select 22386467)

1.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD.

Cancer Chemother Pharmacol. 2014 Aug;74(2):379-87. doi: 10.1007/s00280-014-2499-4. Epub 2014 Jun 18.

PMID:
24939212
2.

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

Nensa F, Stattaus J, Morgan B, Horsfield MA, Soria JC, Besse B, Gounant V, Khalil A, Seng K, Fischer B, Krissel H, Laurent D, Christoph D, Eberhardt WE, Gauler TC.

Future Oncol. 2014 Apr;10(5):823-33. doi: 10.2217/fon.13.248.

PMID:
24799063
3.

Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.

Chatterjee S, Wieczorek C, Schöttle J, Siobal M, Hinze Y, Franz T, Florin A, Adamczak J, Heukamp LC, Neumaier B, Ullrich RT.

Cancer Res. 2014 May 15;74(10):2816-24. doi: 10.1158/0008-5472.CAN-13-2986. Epub 2014 Mar 27.

PMID:
24675359
4.

Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.

Bachelier R, Confavreux CB, Peyruchaud O, Croset M, Goehrig D, van der Pluijm G, Clézardin P.

Int J Cancer. 2014 Sep 15;135(6):1319-29. doi: 10.1002/ijc.28787. Epub 2014 Mar 3.

PMID:
24615579
5.

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.

Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, Rice L, McCarthy K, Johnston SK, Mrugala MM, Chamberlain M.

J Neurooncol. 2014 Mar;117(1):93-101. doi: 10.1007/s11060-014-1358-9. Epub 2014 Jan 22.

PMID:
24449400
6.

Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells.

Ji Y, Chen S, Li K, Xiao X, Xu T, Zheng S.

Br J Dermatol. 2014 Jan;170(1):78-86. doi: 10.1111/bjd.12592.

PMID:
24033364
7.

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology.

Invest New Drugs. 2013 Oct;31(5):1311-20. doi: 10.1007/s10637-013-9978-z. Epub 2013 May 23.

8.

Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety.

Winnik S, Lohmann C, Siciliani G, von Lukowicz T, Kuschnerus K, Kraenkel N, Brokopp CE, Enseleit F, Michels S, Ruschitzka F, Lüscher TF, Matter CM.

Int J Cardiol. 2013 Oct 3;168(3):2453-61. doi: 10.1016/j.ijcard.2013.03.010. Epub 2013 Apr 2.

9.

PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.

Katsura Y, Wada H, Murakami M, Akita H, Hama N, Kawamoto K, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S517-26. doi: 10.1245/s10434-013-2948-z. Epub 2013 Mar 19.

PMID:
23508585
10.

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

Brander D, Rizzieri D, Gockerman J, Diehl L, Shea TC, Decastro C, Moore JO, Beaven A.

Leuk Lymphoma. 2013 Dec;54(12):2627-30. doi: 10.3109/10428194.2013.784969. Epub 2013 Apr 19.

11.

Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.

Weidenaar AC, Ter Elst A, Kampen KR, Meeuwsen-de Boer T, Kamps WA, Schuringa JJ, de Bont ES.

Mol Cancer Res. 2013 Apr;11(4):339-48. doi: 10.1158/1541-7786.MCR-12-0113. Epub 2013 Feb 7.

12.

3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and in vitro evaluation of anticancer activity.

Abouzid KA, Khalil NA, Ahmed EM, Mohamed KO.

Arch Pharm Res. 2013 Jan;36(1):41-50. doi: 10.1007/s12272-013-0007-8.

PMID:
23307426
13.

Image-based high-throughput screening for inhibitors of angiogenesis.

Evensen L, Link W, Lorens JB.

Methods Mol Biol. 2013;931:139-51. doi: 10.1007/978-1-62703-056-4_8.

PMID:
23027002
14.

[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].

Török S, Cserepes T M, Rényi-Vámos F, Döme B.

Magy Onkol. 2012 Sep;56(3):199-208. Epub 2012 Aug 1. Review. Hungarian.

15.

Chronic hypoxia and VEGF differentially modulate abundance and organization of myosin heavy chain isoforms in fetal and adult ovine arteries.

Hubbell MC, Semotiuk AJ, Thorpe RB, Adeoye OO, Butler SM, Williams JM, Khorram O, Pearce WJ.

Am J Physiol Cell Physiol. 2012 Nov 15;303(10):C1090-103. doi: 10.1152/ajpcell.00408.2011. Epub 2012 Sep 19.

16.

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.

Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL; Tumour and Angiogenesis Research Group.

Br J Cancer. 2012 Sep 25;107(7):1044-50. doi: 10.1038/bjc.2012.369. Epub 2012 Aug 21.

17.

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).

Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ.

Pharmacogenomics J. 2013 Oct;13(5):410-6. doi: 10.1038/tpj.2012.23. Epub 2012 Jun 5.

PMID:
22664478
18.

[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].

Török S, Döme B.

Magy Onkol. 2012 Mar;56(1):3-15. doi: MagyOnkol.2012.56.1.3. Epub 2012 Jan 3. Review. Hungarian.

19.

Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats.

Liu S, Xu C, Li G, Liu H, Xie J, Tu G, Peng H, Qiu S, Liang S.

Neurochem Int. 2012 May;60(6):565-72. doi: 10.1016/j.neuint.2012.02.006. Epub 2012 Feb 15.

PMID:
22361062
20.

A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.

Jones SF, Spigel DR, Yardley DA, Thompson DF, Burris HA 3rd.

Clin Adv Hematol Oncol. 2011 Nov;9(11):845-52.

PMID:
22252616
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk